Cerebral infarction is one of the major types of ischemic stroke; it occurs due to the development of one or more clots in the blood vessels that carry blood to the brain. The objective of therapy in acute ischemic stroke is to protect the tissue in the ischemic penumbra, where the blood flow may have reduced but is sufficient enough to stave off infarction. Many surgical and endovascular procedures have been examined in the treatment of acute ischemic stroke.
According to a recently updated publication in the Translational Stroke Research, Interleukin-1 receptor antagonist (IL-1 RA) has been systematically studied on animals and is quite close to receiving acceptance for therapeutics of ischemic stroke. The study includes the comparison of effects of IL-1 RA in live, whole animals with focal cerebral ischemia with that of control groups. After a thorough analysis of 25 studies, the treatment with IL-1 RA is linked with substantial improvements in treatment outcome for ischemic stroke, whether quantified as improved neurobehavioral outcome or reduced infarct volume.
The fact that the prevalence of brain disorders is on the rise globally is supported by statistics from the U.S. National Heart, Lung, and Blood Institute (NHLBI). According to statistics of the NHLBI, almost 4.6 million individuals in the U.S. have cardiac stroke disease, which can transform into brain infarction. These factors will translate into promising growth for the global brain infarction market in the future, says a report by Transparency Market Research.
Q. What are the factors driving the growth of the global cerebral infarction market?
A. The increasing prevalence of brain disorders, increasing incidence of diseases that lead to cerebral infarction, increasing awareness about disease treatment, and technological advancements are the major factors driving the growth of the global cerebral infarction market. In addition, extensive R&D practices, wherein a large spectrum of products are in the pipeline is also propelling this market’s growth. These include drugs such as epoetin alfa, CNTO-0007, AP-102, and others.
Q. What is the developmental scenario of the regional cerebral infarction markets?
A. At present, North America and Europe are the key markets for cerebral infarction as these are traditional research-centered regions and have an increasing prevalence of brain diseases. However, Asia Pacific and some developing nations in Rest of the World are anticipated to emerge as significant markets for cerebral infraction. This is due to increased governmental assistance for research into brain disorders and increasing awareness about neurological diseases in these regions
Q. What are the major lines of treatment for cerebral infarction?
A. The major course of treatment for cerebral infarction include thrombolytic drugs and anti-myocardial infarction drugs among others. Some of the thrombolytic drugs which include tissue plasminogen activator (tPA) have proven their efficacy in the management of cerebral infarction. Other than this, the treatment for cerebral infarction includes eliminating the root cause of the condition, which includes blood pressure drugs, diabetes drugs, and others. Carotid endarterectomy is a major surgical treatment for cerebral infarction.
Thus, it can be concluded that extensive research initiatives will lead to even more effectual treatment for cerebral infarction.